



"Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients."

Cabagnols, Xénia ; Favale, Fabrizia ; Pasquier, Florence ; Messaoudi, Kahia ; Defour, Jean-Philippe ; Ianotto, Jean Christophe ; Marzac, Christophe ; Le Couédic, Jean Pierre ; Droin, Nathalie ; Chachoua, Ilyas ; Favier, Remi ; Diop, M'boyba Khadija ; Ugo, Valérie ; Casadevall, Nicole ; Debili, Najet ; Raslova, Hana ; Bellanne-Chantelot, Christine ; Constantinescu, Stefan N. ; Bluteau, Olivier ; Plo, Isabelle ; Vainchenker, William

Abstract

Mutations in signaling molecules of the cytokine receptor axis play a central role in myeloproliferative neoplasm (MPN) pathogenesis. Polycythemia Vera is mainly related to JAK2 mutations, whereas a wider mutational spectrum is detected in Essential Thrombocythemia (ET) with mutations in JAK2, the thrombopoietin receptor (MPL) and the calreticulin (CALR) genes. Here, we studied the mutational profile of 17 ET patients negative for JAK2V617F, MPLW515K/L and CALR mutations, using Whole Exome Sequencing and Next Generation Sequencing (NGS) targeted on JAK2 and MPL. We found several signaling mutations including JAK2V617F at very low allele frequency, one homozygous SH2B3 mutation, one MPLS505N, one MPLW515R and two MPLS204P mutations. In the remaining patients, four presented a clonal and seven a polyclonal hematopoiesis, suggesting that certain triple negative ETs are not MPNs. NGS on 26 additional triple negative ETs detected only one MPLY591N mutation. Functional studies on MPLS204P ...

Document type : Article de périodique (Journal article)

Référence bibliographique

Cabagnols, Xénia ; Favale, Fabrizia ; Pasquier, Florence ; Messaoudi, Kahia ; Defour, Jean-Philippe ; et. al. *Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients..* In: *Blood*, Vol. 127, no. 3, p. 333-342 (2016)

DOI : 10.1182/blood-2015-07-661983

Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative Essential Thrombocythemia Patients

Xénia Cabagnols*^{1,2,3}, Fabrizia Favale*^{1,2,3}, Florence Pasquier*^{1,2,3}, Kahia Messaoudi^{1,2,3},
Jean Philippe Defour^{4,5}, Jean Christophe Ianotto⁶, Christophe Marzac⁷, Jean Pierre Le
Couédic^{1,2,3}, Nathalie Droin^{1,2,3}, Ilyas Chachoua^{4,5}, Remi Favier^{1,2,3}, M'boyba Khadija
Diop^{1,2,3}, Valérie Ugo⁸, Nicole Casadevall^{1,2,3,7}, Najet Debili^{1,2,3}, Hana Raslova^{1,2,3}, Christine
Bellanne-Chantelot^{1,2,3,9}, Stefan N. Constantinescu^{4,5}, Olivier Bluteau^{1,2,3}, Isabelle Plo§^{1,2,3},
and William Vainchenker§^{1,2,3,10}

¹ INSERM, UMR 1170, Gustave Roussy, Villejuif, France

² Université Paris-Sud, UMR1170, Gustave Roussy, Villejuif, France

³ Gustave Roussy, Villejuif France

⁴ de Duve Institute, Université catholique de Louvain, Brussels, Belgium

⁵ Ludwig Institute for Cancer Research, Brussels, Belgium

⁶ CHU Brest, service d'hématologie, Brest, France

⁷ Assistance Publique-Hôpitaux de Paris, Laboratoire d'Hématologie, Hôpital Saint Antoine, Paris, France

⁸ CHU Brest, Laboratoire d'Hématologie, Brest, France

⁹ Assistance Publique-Hôpitaux de Paris, Département de Génétique, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France

¹⁰ Assistance Publique-Hôpitaux de Paris, Consultation d'hématologie-Immunologie, Hôpital Saint Louis, Paris, France

* These authors contributed equally

§ These authors contributed equally

Running title : MPL and ET

Corresponding author : William Vainchenker UMR U1170, Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, verpre@igr.fr

Key Word: Whole exome sequencing, NGS, essential thrombocythemia, thrombopoietin receptor, mutations

Abstract: 191 words

Manuscript: 3983 words

Keypoints:

-Enrichment of atypical MPL mutations in Essential Thrombocythemia

-*MPLS204P* and *MPLY591N* mutants are weak gain-of-function mutants

Abstract (191)

Mutations in signaling molecules of the cytokine receptor axis play a central role in myeloproliferative neoplasm (MPN) pathogenesis. Polycythemia Vera is mainly related to *JAK2* mutations, whereas a wider mutational spectrum is detected in Essential Thrombocythemia (ET) with mutations in *JAK2*, the *thrombopoietin receptor (MPL)* and the *calreticulin (CALR)* genes. Here, we studied the mutational profile of 17 ET patients negative for *JAK2V617F*, *MPLW515K/L* and *CALR* mutations, using Whole Exome Sequencing and Next Generation Sequencing (NGS) targeted on *JAK2* and *MPL*. We found several signaling mutations including *JAK2V617F* at very low allele frequency, one homozygous *SH2B3* mutation, one *MPLS505N*, one *MPLW515R* and two *MPLS204P* mutations. In the remaining patients, four presented a clonal and seven a polyclonal hematopoiesis, suggesting that certain triple negative ETs are not MPNs. NGS on 26 additional triple negative ETs detected only one *MPLY591N* mutation. Functional studies on *MPLS204P* and *MPLY591N* revealed that they are weak gain-of-function mutants increasing MPL signaling and conferring either TPO hypersensitivity or independence to expressing cells, but with a low efficiency. Further studies should be performed to precisely determine the frequency of *MPLS204* and *MPLY591* mutants in a bigger cohort of MPN.

Introduction

According to the WHO classification, Essential Thrombocythemia (ET), Polycythemia Vera (PV) and Primary Myelofibrosis (PMF) belong to the classical non-BCR-ABL1 Myeloproliferative Neoplasms (MPNs).^{1,2} All the non-BCR-ABL1 MPNs are associated with persistent and hyper-activation of the JAK2/STAT signaling pathway, but ET and PMF are heterogeneous disorders. *JAK2V617F* is the predominant mutation found in 50%-60% of the ET cases.³ Other signaling molecules are mutated in ET including MPL and SH2B3 (LNK). The most prevalent *MPL* mutations in ET and PMF occur on tryptophan 515, an amino acid that maintains MPL in an inactive form in the absence of cytokine. The most frequent mutations are the substitution of W515 to L and K found in 3-5% of ETs and PMFs. Of note, it is the loss of tryptophan, but not the acquisition of a particular residue that induces constitutive activation of MPL,⁴ leading to the MPN phenotype. Less frequently, the S505N mutation located in the exon 10 coding for the transmembrane domain induces a dimerization of the transmembrane helix in an active conformation.⁵ This last mutation has been initially found in some hereditary thrombocytosis,⁶ but has also been detected in rare sporadic ETs and PMFs.^{7,8} In addition, other MPL mutants have already been described, more particularly in the extracellular domain of MPL in very rare ETs and PMFs, but without providing evidence for a gain-of-function.⁸⁻¹² *SH2B3* loss-of-function mutations, are present in less than 1% of ET and PMF, but may not be sufficient to induce a MPN.^{13,14}

Recurrent mutations in the exon 9 of *CALR* have been recently found in around 25% of ETs and PMFs. They all induce a frameshift leading to a new C-terminus peptide composed of at least 35 amino acids with loss of the endoplasmic reticulum (ER) retention signal, KDEL.^{15,16} Whereas wild type *CALR* is essentially involved in the quality control of proteins and in calcium storage in the ER,¹⁷ the *CALR* mutants are able to activate the JAK2/STAT pathway *via* an unknown mechanism like the other MPN driver mutations.¹⁵ The same

signaling mutations are found in ETs and PMFs underscoring they have a close pathogenesis requiring MK hyperplasia although they are clinically different diseases.^{15,16}

Presently the ETs and PMFs, which are negative for *JAK2V617F*, *CALR* and *MPL* mutations are called “triple negative” MPNs.¹ However, the entire sequence of *MPL* is not usually examined in patients. Depending of the particular clinical centers, there is a wide variety of *MPL* mutations that are screened (*MPLW515K/L* or all substitutions of W515 or mutations on exon 10 including *MPLS505N*). Usually only *MPLW515K/L* are searched by allele specific PCR. Whereas the triple negative PMF have a poor prognosis,^{18,19} triple negative ETs have a good prognosis. However, it is presently unknown whether these triple negative MPNs are a homogeneous entity.

In this study we have investigated using Whole Exome Sequencing (WES) the mutational profile of 17 triple negative ET patients previously identified as negative for *JAK2*, *MPL* and *CALR* mutations. This group was heterogeneous with 7 cases that did not display any clonal mutations. In the other cases there was enrichment in *SH2B3* and atypical *MPL* mutations located in the exons 10 and 4 (*MPLS204P*). NGS targeted on *MPL* and *JAK2* exons in 5 of these patients and 26 additional patients lead to the discovery of a second *MPLS204P* mutation not seen in WES and another atypical *MPL* mutation (*MPLY591N*). Sensitive functional studies revealed that both were low gain-of-function mutants. Our results demonstrate that some clonal non-canonical *MPL* gain-of-function mutations are associated with triple negative ETs.

Material and Methods

Patient cohort

Blood samples were obtained from Saint Louis Hospital and Saint Antoine Hospital (Paris) and Brest CHU and approved by the local Ethics Committees. Written informed consent was in accordance with the Declaration of Helsinki. For most of the patients, the diagnosis was performed according to the WHO recommendation including a bone marrow biopsy.^{20,21} *MPLW515K/L* and *JAK2V617F* genotyping were performed by allele-specific q-PCR.^{22,23} The mutational status of *CALR* was determined using previously described high-resolution sizing of fluorescent dye-labeled PCR amplification of exon 9 and Sanger sequencing for validation.²⁴ Plasma TPO levels were measured by Enzyme-Linked ImmunoSorbent Assay according to the manufacturer's instructions (R&D system, Lille, France).

CGH arrays

CGH arrays from granulocytes were conducted on human CGH 2x400K (G4448A) by hybridization of sample *versus* normal-matched commercial reference and a hierarchical clustering was performed²⁵.

Whole Exome Sequencing

WES was performed on genomic DNA (1 µg) from paired samples (granulocytes *versus* T cells) The final libraries were indexed, pooled and sequenced on Illumina HiSeq-2000 sequencer. Only non-synonymous and splice-site mutations were further pursued. A special analysis using BWA ALN for mapping and GATK HaplotypeCaller allowed us to detect insertions and deletions. Candidate mutations observed in the exon sequencing were validated using Sanger sequencing^{15,16,26}.

MPL and JAK2 gene sequencing:

Ion AmpliSeq™ Custom Panel Primer Pools for *MPL* and *JAK2* were used (10 ng of gDNA per primer pool) to perform multiplex PCR but the protocol to generate libraries was modified by adding paired-end adaptors (NEXTflex, Bioo Scientific) to sequence in an Illumina MiSeq flow cell using the onboard cluster method, as paired-end sequencing (2x250 bp reads) (Illumina, San Diego, CA). The entire *MPL* and *JAK2* exons were sequenced to reach a 1000x depth. Minimum variant frequency was set at 1%. Sanger sequencing of the CD3⁺ DNA assessed the somatic status of the mutation.

Cell lines and cell culture

Cytokine-dependent (GM-CSF) human UT7 cell line was cultured in alpha medium 10% SVF, and 5 ng/mL GM-CSF. This UT7 cell line did not express *MPL* and did not response to TPO. IL-3 dependent murine pro-B Ba/F3 cells were cultured in Dulbecco medium with 10% SVF and 5% WEHI.

DNA manipulations, production of retroviruses

The 1531T>A (Y591N), 610T>C (S204P) point mutations were introduced into the MEGIX-human *MPL*-IRES-GFP plasmid by the site-directed mutagenesis method using the PfuUltra high-fidelity DNA polymerase (Stratagene, Agilent Technology, les Ulis, France). Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped viral particles were produced into 293EBNA cells as previously described²⁷.

Flow Cytometry

Cells were labeled with a monoclonal anti-HA antibody conjugated to PE or an isotype control. APC-Annexin V staining was performed according to the manufacturer recommendations (Becton Dickinson (BD), Le Pont de Claix, France). For cell cycle analysis, cells were treated with lysis buffer (sodium acetate with Triton X-100), RNase and labeled with propidium iodide for 30 min. Cells were analyzed on a LSR2 flow cytometer (BD). Data were analyzed with Flow Jo software.

Confocal microscopy

Cells (100,000) were plated on polylysine slides, fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.2% Triton. Primary monoclonal antibodies against GM130 and CALR (Abcam, Cambridge, UK) and HA (Covance, (Eurogenec, Seraing, Belgium) were incubated in BSA 0.2% solution for 1 h followed by secondary goat anti-mouse (Alexa 546) or anti-rabbit (Alexa 633) antibodies (Life technologies, Saint-Aubin, France). DAPI was used to label nuclei. Cells were analyzed using a confocal Leica microscope.

Western Blotting

Signaling studies were performed on UT7 and Ba/F3 cell lines by Western blot analysis of JAK2 (Tyr 1007/1008), STAT1 (Tyr 701), STAT3 (Tyr 705), STAT5 (Tyr 694), ERK1/2 (Thr 202/Tyr 204) and AKT (Thr 308) and of these different pan proteins (Cell Signaling Technology (Ozyme, Saint Quentin en Yvelines, France)). HSC70 (Stressgen, Victoria, Canada) or β -Actin (Sigma, Saint Quentin Fallavier, France) serves as loading control.

STAT5 reporter assay

Gamma 2A JAK2-deficient cells²⁸ were transfected with cDNA coding for MPL or MPL mutants, STAT5, JAK2, Spi-Luc (STAT5 transcriptional reporter) and pRL-TK.^{29,30} After 5 h

the cells were stimulated with 10 ng/mL human TPO. Cells were lysed from 24 h to 48 h later and the luciferase activity was measured, as described.⁴

Cell proliferation

30,000 cells/mL were seeded in a 96 well plate with TPO or GM-CSF at various concentrations. Cell proliferation was quantified 3 days later using WST-1 assay (Takara (Ozyme))³¹. Experiments were done in triplicate. Dose-response curves to TPO were expressed as percent of viability of the maximal response.

Colony formation assay

Twenty cells per well were sorted in a 96 well plate. For each condition, we filled 1 plate with GM-CSF at 5 ng/mL and 8 plates without cytokine. After 3 days, 5 ng/mL GM-CSF or 10 ng/mL TPO were added to perform rescue experiments in half of the plates grown without cytokine. Colony formation was counted at day 8. Each experiment was repeated three times, but the TPO addition was performed in only one experiment.

Results

WES and overview of genetic alterations

We studied 17 patients diagnosed as triple negative ETs namely negative for any *JAK2V617F*, *MPLW515K/L* and *CALR* exon 9 mutations. We performed WES on paired granulocyte and T cell samples that were considered as the tumoral and control cells, respectively. The sequencing coverage mean was 110x and 75% of the target sequences could be analyzed with a coverage above 15x. All candidate mutations with a $p < 0.05$ generated by the bioinformatics analysis were verified by Sanger sequencing.

Sanger sequencing confirmed 22 missense, 4 nonsense and 2 splice mutations, and 3 frame-shifting indels leading to a total of 31 mutations out of 80 candidates. The mutation rate per sample was low (1.82), even in comparison to other myeloid malignancies (Supplemental Table S1). Furthermore, CGH arrays performed on 5 samples were normal.

In a first analysis, three patients displayed previously described *MPL* mutations including two in exon 10 (*MPLW515R* and *MPLS505N*) and one in exon 4 (*MPLS204P*) (Figure 1B). A homozygous nonsense mutation in the *SH2B3* gene was identified in one patient. The unexpected identification of known *MPL* mutations led us to perform deep re-sequencing of all *MPL* and *JAK2* exons resulting in the detection of *JAK2V617F* in one patient and again a *MPLS204P* mutation in another patient (Figure 1C, Supplemental Table S2). These mutations were not seen in WES because of low allelic burden for the *JAK2* mutation (<5%) and low depth of coverage at this position for the *MPLS204P*.

No signaling mutations were identified in the remaining eleven ET patients (Figure 1A). We divided them in clonal and non-clonal disorders, as performed in several previous studies.³²⁻³⁵ Four of them showed a clonal hematopoiesis in granulocytes based on the presence of non-recurrent mutations of unknown function. Seven patients had no detectable clonal mutations

suggesting the presence of a polyclonal hematopoiesis in granulocytes. Neither *CALR* exon 9 mutations nor *JAK2V617F* could be detected in their platelets (data not shown).

Noteworthy, the two *MPLS204P*-positive samples were associated with other mutations: one displayed three other mutations including another driver mutation *ASXLI* and the second presented five mutations different from known MPN driver mutations, but with a mutation of the RNA helicase *HELZ*, which may play a role in oncogenesis (Table 1). The patient identified with an acquired *MPLS505N* mutation (absent in T cells) also exhibited a mutation in *SRSF2* with a higher variant allele frequency suggesting that *MPLS505N* was a secondary event (Table 1). Of interest, this case presented some myelodysplastic features detected by pathology associated with a slight increase in blast count in a bone marrow aspirate. This patient was re-classified as a MDS with a thrombocytosis rather than as a true ET patient. Finally, there was a case exhibiting both homozygous non-sense *SH2B3* and *SF3B1* mutations (Table 1) without any noticeable increase in ring sideroblasts or sign of MDS at bone marrow aspiration, thus eliminating a RARS-T.

Taken together these data indicated that atypical *MPL* mutations seem to be recurrent in the so-called triple negative ET. NGS targeted on *MPL* and on *JAK2* was performed on 31 patients including 5 ETs studied in WES and 26 additional less well-characterized ETs. Another mutation of *MPL* with a variant allele frequency of 9.28% was detected. This missense *MPL* mutation (c.1351T>A) leads to the substitution of a tyrosine by asparagine in the cytosolic domain (Y591N). We also detected a missense mutation in *JAK2* (N1108S) with a variant allele frequency of 50% in both the granulocytes and the T cells. Sequencing of hair DNA confirmed it was a germline mutation (Figure S1). The c.3323A>G has been reported as a rare polymorphism (0.36%). However, the 3D modeling of JAK2N1108S predicts that it may provide a slight gain-of-function based on a higher propensity of formation of a tighter

hydrogen bond between S1108 and N1085, which is linked to the active state of JAK2 kinase domain (Figure S2).

Functional analysis of the MPLS204P mutant

In one of the two *MPLS204P*-positive patients we examined TPO level that was in the normal range (12 pg/mL, normal <30 pg/mL) and comparable to other ETs (range: 8.25-96.1 pg/mL). To study cell surface localization of MPL, we transduced the human factor-dependent UT7 cell line with the HA-tagged MPLWT- and MPLS204P-expressing retrovirus (IRES-GFP). At similar GFP levels, the mean fluorescence intensity of HA labeling was comparable for both receptors using flow cytometry (Figure 2A). Expression of MPLS204P at the cell surface was further confirmed by Western Blotting. A 85 kDa Endoglycosidase-H (Endo-H)-resistant band corresponding to the mature form of MPL was detected for MPLWT and MPLS204P (Figure 2B). The subcellular localization of the two receptors was examined by confocal microscopy. They had a similar localization in the ER (anti-CALR antibody) and Golgi (anti-GM130 antibody) compartments (Figures 2C and D). Finally, we studied the internalization of the receptors after TPO addition using the Ba/F3 cell line. No difference was observed between the MPLWT and MPLS204P (Figure 2E). Taken together, these results suggest that the thrombocytosis was not related to a defect in cell-surface localization of MPLS204P, which would have induced a loss of TPO clearance activity.

We studied the effects of MPLS204P on cell proliferation. MPLS204P did not induce cytokine-independent growth nor it renders cells hypersensitive to TPO or GM-CSF hypersensitivity (Figures 3A and B). In addition, we could not find any difference in apoptosis in the presence (Figure 3C) or absence (Figure 3D) of TPO or in cell cycle at different TPO doses (Figure 3E). No constitutive activation in STAT3, STAT5 and AKT was observed in UT7 cells expressing MPLS204P (Figure 4A). These results suggest that

MPLS204P is a weak gain-of-function mutant. We further used a more sensitive technique to ask whether the MPLS204P was able to support TPO-independent JAK/STAT signaling like MPLW515K.⁴ We employed a luciferase reporter assay for STAT5 activation induced *via* MPL in the JAK2-deficient gamma2A cells.⁴ Expression of MPLS204P supported TPO-independent JAK2/STAT5 signaling, albeit to lower levels than MPLW515K (Figure 4B). Of interest, while MPLW515K-induced JAK2/STAT5 activation was evident at 24-30 h after transfection, a longer period was necessary for MPLS204P (> 40 h). This indicates that the MPLS204P mutant signals are weaker than those induced by MPLW515K.

Finally, we tested whether MPLS204P could induce prolonged signaling in UT7 cells. Cells were stimulated with 10 ng/mL TPO, subsequently washed and then cultured without cytokine for 3 h. A sustained phosphorylation of STAT5 and AKT was observed for the mutant cells (Figure 4C). To demonstrate that this weak constitutive activity exerts some biological consequence a limiting dilution of MPLWT and MPLS204P UT7 cells (twenty cells per well in a 96-well plate) were grown without cytokine for one week (Figure 5A). Autonomous growth numbered as colonies was observed with UT7 MPLS204P (5%-10%), but not with UT7 MPLWT, except in rare wells suggesting that around 0.25% of UT7 cells became cytokine-independent due to MPLS204P. Furthermore, after 3 days of culture without cytokines we added GM-CSF or TPO for rescue, and observed a 2 to 4-fold increased cloning efficiency for UT7 MPLS204P compared to MPLWT (Figures 5B and C).

Altogether these results demonstrate that MPLS204P is a gain-of-function mutant.

Functional analysis of the MPLY591N mutant

We conducted the functional analysis of another MPL mutant identified by NGS using Ba/F3 cells lines. Flow cytometry analysis showed that MPLY591N was addressed more efficiently (1.63 ± 0.07 fold) to the cell surface membrane compared to MPLWT at similar GFP levels (Figure 6A), indicating either an increased trafficking of MPL mutant to cell

surface or a decreased internalization. We measured the impact of this mutant on cellular proliferation in response to TPO. MPLY591N conferred a 4- to 5-fold hypersensitivity to TPO compared with MPLWT (IC₅₀ of 0.10 ng/mL for WT and 0.02 ng/mL for Y591N), but without spontaneous growth in the absence of cytokine (Figure 6B).

We next verified the effect of MPLY591N mutant on signaling in Ba/F3 cells by Western Blot analysis. Noticeably, these cells expressed similar levels of exogenous MPL. Interestingly, a constitutive phosphorylation of STAT3, STAT5 and ERK was observed in MPLY591N mutant cells compared with MPLWT cells. The TPO dose-dependent increase in the phosphorylation of these molecules was higher in presence of MPLY591N than MPLWT. No difference was observed on AKT or STAT1 phosphorylation (Figure 6C).

Altogether, these results show that MPLY591N is also a weak gain-of-function mutation that leads to TPO hypersensitivity without independent growth and to a partial spontaneous activation of signaling pathways.

Discussion

The goal of this work was to characterize the mutational genomic profile of triple negative ETs using WES. Among the 17 triple negative ETs, we considered that 7 had a polyclonal hematopoiesis in granulocytes as no mutation was detected by WES. This molecular approach has clear limitation because it cannot detect mutations in non coding sequences and gene fusion and even more cannot detect mutations in coding sequences at low variant allele frequency (VAF). In this work, we defined clonal hematopoiesis as the presence of any somatic mutation either in a known driver of hematopoietic malignancies or in another gene (passenger mutation),³²⁻³⁵ but without using X chromosome inactivation assays except in two cases where results were concordant. It has been calculated that each normal HSC accumulates 0.13 mutation per year in coding sequences³⁶. Thus, it is expected that in the case of clonal hematopoiesis in patients older than 50, several mutations would be found. However, the technique has a sensitivity of around 10% for VAF. Thus, it seems likely that this “polyclonal” triple negative thrombocytosis cases can be MPNs with a low VAF in granulocytes similar to *JAK2V617F* ET in which VAF is much higher in platelet RNA than in granulocyte DNA³⁷. Therefore, it will be important in the future to directly perform WES or whole genome sequencing on megakaryocyte or to sequence platelet RNA. Alternatively, some of these disorders can be other diseases than MPNs, more particularly hereditary thrombocytosis. In the co-submitted paper, germline gain-of-function mutations in *JAK2* and *MPL* were found in triple negative ETs.³⁸ Hereditary thrombocytosis may arise without other familial cases if the patient is the founder. In one case, we detected a germline mutation in *JAK2* (N1108S) that appears in *in silico* modeling as a possible gain-of-function mutation, suggesting a hereditary thrombocytosis. However this mutation has also been described as a rare polymorphism. Thus we cannot exclude that rare *JAK2* or *MPL* variants, which may be present in the general population, can induce a MPN disease in certain individuals.

The enrichment in previously described rare signaling mutations,⁹ was striking in triple negative ETs. One was a homozygous nonsense mutation in *SH2B3*. Heterozygous *SH2B3* mutations were reported in MPNs and it is discussed whether by themselves they could give rise to a MPN.¹⁴ In some cases they are associated with *JAK2V617F*.³⁹ Here, the mutation is homozygous and because mice totally deficient in *Sh2b3* develop a myeloproliferative disorder,⁴⁰ we can suggest that this homozygous mutation leading to an absence of LNK was really the driver of the MPN. Interestingly, a *SF3B1* mutation was associated with this homozygous *SH2B3* mutation, but the phenotype of the disease was an ET.

Four mutations in *MPL* were found in the first series of patients, including *MPLS505N* and *MPLW515R* located in exon 10 that are not commonly screened. The later were somatic mutations in our study although they can also be identified as germline mutations in hereditary thrombocytosis.^{6,41}

In two other patients we detected an acquired *MPLS204P* mutation. This mutation has been previously described in a myelofibrosis, and a S204F mutation was described in another myelofibrosis case.^{10,12} In the co-submitted manuscript paper, S204P and S204F mutations were detected in two triple negative patients.³⁸ It is interesting to note that mouse *MPL* residue 204 is a proline instead of a serine in human *MPL*, thus the S204P mutation restores the mouse *MPL* sequence into the human *MPL*. Moreover, the germline mutation K39N (*MPL* Baltimore) present in a heterozygous form in 7% of African-American population also restores a mouse sequence and is associated with a thrombocytosis.⁴² It is tempting to assume that differences between the human and mouse *MPL* sequences may contribute to the high platelet count in mice associated with an elevated plasma TPO level in comparison to the situation in humans. In the case of the K39N, there is evidence that the membrane expression level of the *MPL* mutant is lower than *MPL*WT and this can explain a thrombocytosis phenotype due to a decreased TPO clearance activity of *MPL*, which is in great part related to

the expression level of MPL on the surface of mature megakaryocyte and platelets.⁴² This has been well demonstrated in 3 murine models.⁴³⁻⁴⁵ Here, we clearly demonstrate that the thrombocytosis induced by MPLS204P is not due to a defect in cell trafficking of the receptor. In contrast, MPLS204P is a weak gain-of-function mutant in signaling, inducing a constitutive STAT activation using sensitive approaches and an increased and more prolonged ligand-induced STAT phosphorylation than MPLWT. Using limiting dilution techniques, it was possible to demonstrate that MPLS204P could induce cytokine-independent growth with a low efficiency in around 1/400 UT7 cells. Furthermore, UT7 MPLS204P cells were more resistant than UT7 MPLWT cells to a 3-day cytokine deprivation. The two cases with MPLS204P were associated with several other mutations: one with *ASXLI*, the second with a mutation in an RNA helicase implicated in proliferation. Thus, we suspect that these mutants with a very low oncogenic potential, would need to be associated to other drivers to give rise to a MPN.

Finally, we detected a MPLY591N mutant in one patient. MPLY591D has been previously described in a PV patient in association with a heterozygous *JAK2V617F* mutation¹⁰ as reported in the co-submitted manuscript. Here, we detected the MPLY591N in the absence of a *JAK2* mutation. This mutation was assumed to be a gain-of-function for two reasons. Previously it was shown that this tyrosine also called 78 (intracellular tyrosine) is phosphorylated on the MPLW515A and that the double mutant MPLW515A/Y591F induced a much more severe MPN in the mouse than the single MPLW515A mutant.⁴⁶ Furthermore, this tyrosine is also phosphorylated after TPO binding, and negatively regulates MPL signaling by promoting its internalization degradation as well as ERK signaling.^{46,47 48} Asparagine is a polar residue in contrast to the negative charge represented by tyrosine phosphorylation and thus the Y591N mutation resembles a Y591 loss-of-function, like Y591F, but possibly weaker since unlike phenylalanine, asparagine is polar. When the Y591N mutant

was expressed in Ba/F3 cells it induced a slight TPO hypersensitivity, which was associated to a constitutive activation of STAT3 and ERK. In the *MPLY591N*-positive patient, we did not perform WES to assess whether other driver mutations were present, as for *MPLS204P*. However, this mutant was detected in a case of ET occurring in a familial form of MPN where we have recently identified the predisposition locus consisting of a 700-kb duplication involving 6 genes. The overexpression of two of them, *ATG2B* and *GSKIP*, induces TPO hypersensitivity and cooperates with *JAK2*, *MPL* and *CALR* mutations to give an ET.²⁵ Thus, the predisposition locus could be the initiating event and the low gain-of-function *MPLY591N* could be sufficient to induce an overt ET.

Altogether this study has shown that in a fraction of the so-called triple negative ETs a significant proportion of patients have mutations in signaling molecules, more particularly in *MPL*. This group of patients appears heterogeneous including some with a polyclonal hematopoiesis as previously shown in pediatric ETs.⁴⁹ Further studies using whole exome sequencing and RNA sequencing will be required to better understand the pathogenesis of these ETs.

Acknowledgments

We want to thank E. Leroy for modeling JAK2N1108S and the bioinformatic platform of Gustave Roussy for analyzing the NGS experiments. We are grateful to P. Rameau for cell sorting experiments. Support to SNC is acknowledged from Ludwig Institute, Salus Sanguinis, Fondation contre le cancer, Fonds National de la Recherche Scientifique, Inter-University Attraction Pole and Action de recherche concertée projects, Belgium. This work was funded by grants from the Agence Nationale pour la Recherche (Thrombocytosis, WV), the Ligue Nationale contre le Cancer (équipe labellisée), the Fondation Laurette Fugain (WV, IP),

Agence Nationale pour la Recherche-Jeune Chercheur (IP), a specific grant from Gustave Roussy (taxe d'apprentissage) and from the INSERM. IC was supported by a FRIA fellowship. XC was supported by the university Paris-Diderot, FF by the INSERM (poste d'accueil) and FP by the Fondation pour la recherche contre le Cancer.

Author contribution

WV, IP, designed and performed research, analyzed data, prepared figures, and wrote the paper; performed research and analyzed data; XC performed and interpreted pangenomic analysis, prepared figures and wrote the paper; FF and FP performed functional analysis, prepared figures and wrote the paper; KM performed functional analysis and prepared figures; JPD and IC performed luciferase assays; JCI, VU and NC were involved in clinical part; RF performed the TPO Elisa assays; CM performed the CALR sizing and provided genotyped samples; JPLC and ND performed the WES; MKD did bioinformatics study of exome data; OB collected samples, performed the targeted NGS approach and prepared figures; ND, HR and SC gave an experimental/intellectual input and corrected the manuscript; CBC provided samples, interpreted the NGS, gave an experimental/intellectual input and all authors contributed to editing.

Contribution Conflict-of-interest disclosure: The authors declare no potential conflict of interest.

References

1. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. *Leukemia*. 2014;28(7):1407-1413.
2. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. *Int J Hematol*. 2010;91(2):174-179.
3. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. *Semin Cell Dev Biol*. 2008;19(4):385-393.
4. Defour JP, Itaya M, Gryshkova V, et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(7):2540-2545.
5. Ding J, Komatsu H, Iida S, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. *Blood*. 2009;114(15):3325-3328.
6. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. *Blood*. 2004;103(11):4198-4200.
7. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood*. 2008;112(1):141-149.
8. Chaligne R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. *Leukemia*. 2008;22(8):1557-1566.
9. He X, Chen Z, Jiang Y, Qiu X, Zhao X. Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. *J Hematol Oncol*. 2013;6:11.
10. Kawamata N, Ogawa S, Yamamoto G, et al. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. *Exp Hematol*. 2008;36(11):1471-1479.
11. Lambert MP, Jiang J, Batra V, Wu C, Tong W. A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. *Am J Hematol*. 2012;87(5):532-534.
12. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. *Exp Hematol*. 2007;35(11):1641-1646.
13. Koren-Michowitz M, Gery S, Tabayashi T, et al. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. *Br J Haematol*. 2013;161(6):811-820.
14. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. *Blood*. 2010;116(6):988-992.
15. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. 2013;369(25):2379-2390.
16. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med*. 2013;369(25):2391-2405.
17. Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. *Int J Biochem Cell Biol*. 2012;44(6):842-846.
18. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*. 2014;124(16):2507-2513; quiz 2615.
19. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia*. 2014;28(7):1472-1477.

20. Cervantes F, Barosi G. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. *Seminars in oncology*. 2005;32(4):395-402.
21. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. *British journal of haematology*. 1999;104(4):730-737.
22. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005;434(7037):1144-1148.
23. Chaligne R, James C, Tonetti C, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. *Blood*. 2007;110(10):3735-3743.
24. Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. *Leukemia*. 2015;29(1):249-252.
25. Saliba J, Saint-Martin C, Di Stefano A, et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. *Nature genetics*. 2015.
26. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. *Cancer discovery*. 2014;4(9):1088-1101.
27. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. *Blood*. 2008;112(4):1402-1412.
28. Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. *Molecular and cellular biology*. 1997;17(2):695-706.
29. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. *The Journal of biological chemistry*. 2002;277(49):47954-47963.
30. Sliva D, Wood TJ, Schindler C, Lobie PE, Norstedt G. Growth hormone specifically regulates serine protease inhibitor gene transcription via gamma-activated sequence-like DNA elements. *The Journal of biological chemistry*. 1994;269(42):26208-26214.
31. Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. *Blood*. 2014;123(9):1372-1383.
32. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nature medicine*. 2014;20(12):1472-1478.
33. McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. *Cell reports*. 2015;10(8):1239-1245.
34. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *The New England journal of medicine*. 2014;371(26):2477-2487.
35. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *The New England journal of medicine*. 2014;371(26):2488-2498.
36. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Cancer cell*. 2014;25(3):379-392.
37. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. *Blood*. 2006;108(12):3913-3915.
38. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. *Blood*. 2014;Co-submitted.
39. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. *Leukemia*. 2010;24(10):1713-1718.
40. Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. *The Journal of experimental medicine*. 2002;195(12):1599-1611.
41. Vilaine M, Gourain V, Cleyrat C, et al. Germline MPLW515R mutation in a family with isolated thrombocytosis 2012;54nd Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta(Myeloproliferative Syndromes - Basic Science: Poster I).

42. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(31):11444-11447.
43. Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC. Incomplete restoration of Mpl expression in the *mpl*^{-/-} mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. *Blood*. 2009;113(8):1778-1785.
44. Meyer SC, Keller MD, Woods BA, et al. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. *Blood*. 2014;124(14):2280-2284.
45. Ng AP, Kauppi M, Metcalf D, et al. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(16):5884-5889.
46. Pecquet C, Staerk J, Chaligne R, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. *Blood*. 2010;115(5):1037-1048.
47. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. *Proceedings of the National Academy of Sciences of the United States of America*. 1997;94(6):2350-2355.
48. Sangkhae V, Saur SJ, Kaushansky A, Kaushansky K, Hitchcock IS. Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling. *Experimental hematology*. 2014;42(6):477-486 e474.
49. Karow A, Nienhold R, Lundberg P, et al. Mutational profile of childhood myeloproliferative neoplasms. *Leukemia*. 2015.

Figure legends

Figure 1: Genomic analysis

A) A schematic representation of the signaling mutations in the 17 patients and of the type of hematopoiesis in triple negative ETs. We consider as polyclonal ETs the patients that exhibit no mutation (driver or passenger) in WES. **B) Sanger sequencing of MPLS204P.** Nucleotides and amino acid numbers are indicated.

Figure 2: MPLS204P does not exhibit cellular trafficking defects

A) MPL cell-surface expression analysis by flow cytometry. UT7 cells transduced with either the HA-tagged MPLWT or HA-tagged MPLS204P receptor were incubated with an anti-HA antibody coupled with PE. Histograms show equivalent GFP expression (left) monitoring the total MPL levels and HA-PE labeling (right) corresponding to similar cell-surface expression

of MPLWT and MPLS204P. **B) Analysis of the different forms of MPL.** UT7 MPLWT and MPLS204P cell extracts were treated with EndoH (500 U, overnight at 37°C) and Western blot analysis was performed using anti-HA antibody. Figure shows the different forms of MPL with EndoH-resistant mature form corresponding to a 85 kDa band which is equivalent in both cell lines. Samples were run on the same gel and vertical lines have been inserted to indicate a repositioned gel lane. **C) Localization of MPL in the endoplasmic reticulum (ER) and D) in the Golgi apparatus.** MPLWT and MPLS204P UT7 cells were analyzed by immunofluorescence using an anti-CALR (ER marker), an anti-GM130 (Golgi apparatus marker) and an anti-HA (MPL detection) antibodies. **E) Internalization of the MPLWT and MPLS204P after TPO binding.** These experiments were performed with Ba/F3 cells expressing either MPLWT or MPLS204P. MPL cell surface expression was studied by flow cytometry after TPO addition. Results are means \pm SD of 3 independent experiments.

Figure 3: MPLS204P does not present proliferative advantage in bulky cultures

A and B) Cell proliferation induced by TPO of MPLWT and MPLS204P UT7 cells. Cells were cultured in the presence of various concentrations of TPO (A) or GM-CSF (B) for 72 h. Viable cells were quantified by WST-1 proliferation assay. Dose-response curves are means \pm SEM (n=3 in triplicate). **C and D) Apoptosis analysis in MPLWT and MPLS204P UT7 cells.** (C) Cells were cultured for 2 days with various concentration of TPO (0.01, 0.05 and 10 ng/mL) and the percentage of apoptotic cells (Annexin V positive) was analyzed by flow cytometry using Annexin V assay. (D) Cells were cultured for 24 h with TPO (10 ng/mL) followed by overnight deprivation. The percentage of apoptotic cells (Annexin V-positive) was analyzed at different times after TPO removal (1, 2, 3 and 4 days). **E) Cell cycle analysis of MPLWT and MPLS204P UT7 cells.** Cells were cultured for 2 days with various

concentration of TPO (0.01, 0.05 and 10 ng/mL) and the percentage of cells in G1, S and G2 phases were determined after propidium iodide labeling, by flow cytometry analysis.

Figure 4: MPLS204P is a weak gain-of-function mutant

A) Signaling studies induced by high TPO concentration in MPLWT and MPLS204P UT7 cells. After cytokine deprivation, cells were stimulated with TPO (100 ng/mL for 5 min, 30 min or 2 h). The phosphorylation status of STAT3, STAT5, AKT and ERK1/2 was examined by Western blotting and results were compared to cells stimulated by GM-CSF (5 ng/mL). **B) STAT5 transcriptional activity in Gamma 2A JAK2-deficient cells expressing MPLWT or MPLS204P.** Cells were transfected with cDNAs coding for MPLWT or MPLS204P, JAK2, STAT5 and with Firefly STAT5 luciferase reporter spi-Luc and pRL-TK vectors coding for renilla luciferase. Luminescence was measured after 48 h transfection. Shown are average units \pm SEM of one representative experiment performed in triplicate out of three. **C) Persistent signaling in UT7 MPLS204P.** UT7 MPLWT and UT7 MPLS204P were stimulated by TPO (10 ng/mL) for 10 min and subsequently washed. A 3 h time-course was performed followed with Western blotting, as in previous figures. MPLWT and MPLS204P samples were run on the same gel. P-STAT5/STAT5 or P-ERK/ERK ratios are indicated after quantification by image J software.

Figure 5: UT7 MPL S204P cells are less cytokine-dependent than UT7 MPL WT.

A) Growth of UT7 MPLS204P and UT7 MPLWT at limiting dilution without cytokines. Cells (20 per well) were cultured without cytokines in a 96-well plate. Colony growth were counted one week later. **B) Rescue experiments by GM-CSF.** Cells (20 per well) were cultured without cytokines in a 96-well plate. After 3 days, GM-CSF (5 ng/mL) was added and colonies were counted one week later. **C) Rescue experiments by TPO.** Cells (20 per

well) were cultured without cytokines in a 96-well plate. After 3 days, TPO (10 ng/mL) was added and colonies were counted one week later. Results represent the means \pm SD of the number of colonies /96-well plate. Each point corresponds to number of clone in one plate.

Figure 6: Analysis of the MPLY591N mutant.

A) *MPL cell-surface localization in Ba/F3 cells.* Ba/F3 cells expressing the bicistronic retroviral pMEGIX-IRES-GFP vector encoding HA-tagged MPLWT or MPLY591N and GFP were maintained in IL3-supplemented medium. Flow cytometry analysis was assessed and histograms show equivalent GFP expression (left) monitoring the total MPL levels and HA-PE labeling (right) corresponding to cell-surface expression of MPLWT and MPLY591N. **B) *Sensitivity to TPO of Ba/F3 cells.*** Ba/F3-MPLWT or MPLY591N cells were cultured for 72 h either in absence of cytokine (black arrow, X axis) or in presence of increasing doses of TPO (0.01, 0.1, 1 and 10 ng/mL). Viable cells were quantified by WST-1 proliferation assay. Dose-response curves are means expressed in percentages of maximum growth value \pm SEM (n=3 in triplicate). Two-tailed *t*-test, * <0.05 **, $p<0.01$. **C) *Signaling studies in Ba/F3-MPL cells.*** Ba/F3-MPLWT or MPLY591N cells were serum- and cytokine-starved for 6 h prior to a 15 min stimulation without or with TPO (0.01, 0.1, 1 and 10 ng/mL) as indicated. Cells were lysed and the phosphorylation status of STAT1, STAT3, STAT5, AKT and ERK1/2 was examined by Western blotting with the respective anti-phospho specific antibodies, as indicated. MPL expression was also verified. Expression of β actin in the samples was used as loading control and was consistent with expression of total AKT, ERK1/2 and the individual STAT isoforms. Blots shown were reproduced in three independent experiments.

Table 1: Mutational profile in granulocytes from 10 ET patients by exome sequencing.

The % of variant allele frequency is indicated in brackets.

Sample	Mutations					
3	SCNN1G (21.34)					
12	SHOC2 (22.22)	CASC5 (25.0)				
14	MPL S204P (19.26)	ASXL1 (20.97)	EDA (41.18)			
21	KPNA1 (28.21)	VPS13D (39.29)	EEA1 (39.79)	SF3B1 (54.55)	SH2B3 (98.33)	
24	FUBP1 (23.88)	PPP1R3 7 (30.77)	COMP (36.14)	ADCY5 (36.67)	HELZ (37.25)	MPL S204P (47.74)
25	ATXN7L1 (21.95)					
32	LYZL2 (30.77)					
91	MPL S505N (23.02)	DDI1 (24.18)	IMPG2 (24.24)	PPP2R5 A (43.75)	SRSF2 (44.35)	APOL4 (86.52)
92	JAK2 V617F (11.77)	ALDH3A 2 (28.12)				
98	MPL W515R (23.94)					

Figure 1.





Figure 2.




Figure 3.






Figure 4.

A



B



C






Figure 5.


A



B



C





blood

Prepublished online October 8, 2015;
doi:10.1182/blood-2015-07-661983

Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients

Xénia Cabagnols, Fabrizia Favale, Florence Pasquier, Kahia Messaoudi, Jean Philippe Defour, Jean Christophe Ianotto, Christophe Marzac, Jean Pierre Le Couédic, Nathalie Droin, Ilyas Chachoua, Remi Favier, M'boyba Khadija Diop, Valérie Ugo, Nicole Casadevall, Najet Debili, Hana Raslova, Christine Bellanne-Chantelot, Stefan N. Constantinescu, Olivier Bluteau, Isabelle Plo and William Vainchenker

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.